Regulatory Strategy for Pre-IND Meetings with FDA: Why ...

from the FDA provided to the Sponsor within 21 days of the FDA’s receipt of the meeting request. In the last few years certain Offices within the FDA, such as the Office of Vaccines Research and Review (OVRR), may deny phase 3 pre-IND meeting requests, and require the Sponsor to submit a Master File (MF) instead to allow sufficient ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download